Attenuation of methotrexate induced hepatotoxicity by epigallocatechin 3-gallate
Methotrexate (MTX) is currently used as first-line therapy for autoimmune diseases like rheumatoid arthritis, psoriasis, and systemic lupus erythematous. However, its use is limited by its hepatotoxic potential. Epigallocatechin-3-gallate (EGCG), an abundant catechin present in tea possesses potent antioxidant activity and effectively ameliorates oxidative stress-related disorders. This study aimed to investigate the hepatoprotective influence of EGCG in a MTX-induced rat model of hepatotoxicity. Sprague Dawley rats pretreated with EGCG (40 mg kg-1 b.w., p.o.) were administered a single dose of MTX (20 mg kg-1 b.w., i.p.) and its hepatoprotective efficacy compared with folic acid (1 mg kg-1 b.w., i.p.). On day 10, blood samples were collected to determine plasma levels of aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), while the livers were examined for histopathogical changes along with levels of oxidative stress measured in terms of myeloperoxidase (MPO) activity, protein carbonylation (PCO), lipid peroxidation (LPO), and activities of cellular enzymatic antioxidants - superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). MTX significantly increased the plasma levels of AST, ALT, ALP, and LDH, which were prevented by pretreatment with EGCG, and was corroborated by histopathology. Additionally, MTX-induced hepatic oxidative stress as measured by increased generation of MPO, enhanced PCO, LPO, and decreased activities of antioxidant enzymes was mitigated by pretreatment with EGCG. The amelioration of MTX-induced hepatotoxicity by EGCG endorsed the inclusion of an anti-oxidant during chronic administration of MTX.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Drug and chemical toxicology - 46(2023), 4 vom: 01. Nov., Seite 717-725 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pradhan, Ayan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 29.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/01480545.2022.2085738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342204157 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342204157 | ||
| 003 | DE-627 | ||
| 005 | 20231226013547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/01480545.2022.2085738 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342204157 | ||
| 035 | |a (NLM)35698845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pradhan, Ayan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Attenuation of methotrexate induced hepatotoxicity by epigallocatechin 3-gallate |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 29.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Methotrexate (MTX) is currently used as first-line therapy for autoimmune diseases like rheumatoid arthritis, psoriasis, and systemic lupus erythematous. However, its use is limited by its hepatotoxic potential. Epigallocatechin-3-gallate (EGCG), an abundant catechin present in tea possesses potent antioxidant activity and effectively ameliorates oxidative stress-related disorders. This study aimed to investigate the hepatoprotective influence of EGCG in a MTX-induced rat model of hepatotoxicity. Sprague Dawley rats pretreated with EGCG (40 mg kg-1 b.w., p.o.) were administered a single dose of MTX (20 mg kg-1 b.w., i.p.) and its hepatoprotective efficacy compared with folic acid (1 mg kg-1 b.w., i.p.). On day 10, blood samples were collected to determine plasma levels of aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), while the livers were examined for histopathogical changes along with levels of oxidative stress measured in terms of myeloperoxidase (MPO) activity, protein carbonylation (PCO), lipid peroxidation (LPO), and activities of cellular enzymatic antioxidants - superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). MTX significantly increased the plasma levels of AST, ALT, ALP, and LDH, which were prevented by pretreatment with EGCG, and was corroborated by histopathology. Additionally, MTX-induced hepatic oxidative stress as measured by increased generation of MPO, enhanced PCO, LPO, and decreased activities of antioxidant enzymes was mitigated by pretreatment with EGCG. The amelioration of MTX-induced hepatotoxicity by EGCG endorsed the inclusion of an anti-oxidant during chronic administration of MTX | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-oxidant | |
| 650 | 4 | |a epigallocatechin-3-gallate (EGCG) | |
| 650 | 4 | |a hepatoprotective effect | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a tea | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a gallocatechol |2 NLM | |
| 650 | 7 | |a HEJ6575V1X |2 NLM | |
| 650 | 7 | |a epigallocatechin gallate |2 NLM | |
| 650 | 7 | |a BQM438CTEL |2 NLM | |
| 650 | 7 | |a Catechin |2 NLM | |
| 650 | 7 | |a 8R1V1STN48 |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Alkaline Phosphatase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.1 |2 NLM | |
| 700 | 1 | |a Sengupta, Shilpa |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Ritika |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Mitali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and chemical toxicology |d 1984 |g 46(2023), 4 vom: 01. Nov., Seite 717-725 |w (DE-627)NLM000913685 |x 1525-6014 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:4 |g day:01 |g month:11 |g pages:717-725 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/01480545.2022.2085738 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 4 |b 01 |c 11 |h 717-725 | ||